PIK3CA and head and neck squamous cell carcinoma: Our in vitro data demonstrated strong synergism of the combination treatment with rapamycin and trametinib against HNSCC -derived cells exhibiting quite distinct genomic alterations, including cells carrying endogenous and genetically engineered RAS or PIK3CA mutations.